Equillium announces abstract accepted for oral presentation at ASTCT, CIBMTR

Equillium announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy, ASTCT, and the Center for International Blood & Marrow Transplant Research, CIBMTR. The Hybrid meetings will take place virtually and in person at the Orlando World Center Marriott, Orlando, Florida, February 15 – 19, 2023. The abstract highlights positive final study results, including long-term follow-up data for up to one year, from EQUATE, a Phase 1b study of itolizumab in combination with corticosteroids to treat subjects with newly diagnosed severe acute graft-versus-host disease. The data demonstrate promising outcomes in subjects with severe aGVHD, and Equillium has since initiated EQUATOR, a Phase 3 study of itolizumab as a potential initial therapy for aGVHD in combination with CS.